A

Rating buyAI Memo

Agilent

As of 2026-09-16/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-16 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

medium

Horizon

6‑12m

Key catalyst

Q4 execution against raised FY2026 outlook • 2026-10-31

Base target: $160 / p=50% prob

Biggest risk

Some Q3 EPS and margin upside came from tariff refunds, creating a tougher quality-of-earnings comparison. The packet also lacks a verified post-print analyst-revision set, while acquisition integration and continued end-market recovery remain execution dependencies.

Invalidation

Break below $128 or thesis failure.

What would change my mind?

Q3 revenue grew 7.3% on a core basis, underlying operating margin exceeded implied guidance, and management raised FY2026 revenue, margin, and EPS expectations. Improving end markets, new-product response, and operating discipline could sustain above-market growth [#SEC-8K-2026-08-26][#PR-EARNINGS-2026-08-31].

Research note

Recommendation

buy

Confidence

medium

As of

2026-09-16

Base target

$160

p=50%

Bull target

$178

p=30%

Bear target

$128

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Underlying earnings must offset the nonrecurring tariff benefit
Biocare acquisition and pathology expansion
Q3 revenue grew 7.3% on a core basis, underlying operating margin exceeded implied guidance, and management raised FY2026 revenue, margin, and EPS expectations.

BearKey bullets

Biocare closing or integration delays could defer expected pathology benefits; completion is not confirmed in the supplied evidence.
Board transition following Koh's retirement warrants monitoring, although the filing states that the decision did not result from a disagreement with Agilent [#8-K-2026-09-08].
End-market improvement may prove uneven, limiting instrument replacement demand and operating leverage.

WatchKey bullets

Q4 execution against raised FY2026 outlook

Summary

High-level snapshot

Recommendation

buy

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $160 (p=50%)

Target spread vs base: +11% / -20%

Scenario probabilities

Bull Target: $178 (p=30%)Base Target: $160 (p=50%)Bear Target: $128 (p=20%)

Commentary

Primary-source tone is constructive following the Q3 beat and raised FY2026 outlook. However, no reliable social, options, short-interest, employee-sentiment, immediate post-release price-reaction, or verified analyst-revision data were supplied; unavailable sentiment fields are left neutral rather than treated as positive evidence. The setup remains favorable but requires Q4 confirmation without another tariff refund [#SEC-8K-2026-08-26].

As of 2026-09-16 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Underlying earnings must offset the nonrecurring tariff benefit
Biocare acquisition and pathology expansion

Scenarios

Bull Target (Scenario probability)

$178 / p=30% prob

Base Target (Scenario probability)

$160 / p=50% prob

Bear Target (Scenario probability)

$128 / p=20% prob

Analysis 2026-09-16 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.62

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-31
Q4 execution against raised FY2026 outlook
Agilent guided Q4 revenue to $1.98-$2.00 billion, core growth to 5.2%-6.2%, and non-GAAP EPS to $1.71-$1.74 after Q3 revenue and EPS exceeded prior guidance. Delivery would reinforce the operating-momentum thesis [#SEC-8K-2026-08-26].
Prob 72.00% • Move 5.00% • Priced-in 65.00%

Short-term Catalysts

Next few weeks

Underlying earnings must offset the nonrecurring tariff benefit
2026-10-31
Q3 non-GAAP EPS included a $0.06 tariff-refund benefit, while Q4 guidance assumes no future tariff refunds. Failure to sustain margins without that benefit could weaken the positive earnings interpretation [#SEC-8K-2026-08-26][#PR-EARNINGS-2026-08-31].
Prob 65% • Move -4% • Priced-in 55%

Long-term Catalysts

Months to a year

Biocare acquisition and pathology expansion
2026-10-31
The previously announced Biocare Medical acquisition was targeted to close by fiscal Q4 2026. Timely completion and integration could expand Agilent's pathology exposure, but the packet does not confirm completion as of the analysis date [#PR-2026-03-09].
Prob 65% • Move 5% • Priced-in 45%

Risks

Biocare closing or integration delays could defer expected pathology benefits; completion is not confirmed in the supplied evidence.
Board transition following Koh's retirement warrants monitoring, although the filing states that the decision did not result from a disagreement with Agilent [#8-K-2026-09-08].
End-market improvement may prove uneven, limiting instrument replacement demand and operating leverage.
Q4 margin or EPS delivery could disappoint when the $0.06 Q3 tariff-refund benefit does not recur [#SEC-8K-2026-08-26].
The absence of a verified post-print analyst-revision set limits confidence in target and estimate support.

Peers

Symbol	Summary
BRKR	Focused analytical-instruments comparator useful for determining whether replacement-cycle demand is industry-wide or Agilent-specific [#10-K-2025-12-22].
DHR	Broad diagnostics and analytical-instruments benchmark relevant to pathology and laboratory-workflow execution [#10-K-2025-12-22].
TMO	Large life-science tools and services benchmark for end-market demand and mix, although its broader portfolio makes it less comparable than a pure-play instrument vendor [#10-K-2025-12-22].
WAT	Direct analytical-instruments and laboratory-workflow comparator for evaluating replacement demand and service attachment; Agilent previously identified Waters as a principal competitor [#10-K-2025-12-22].

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-16

Loading AI feed…

Symbol

Summary

BRKR

Focused analytical-instruments comparator useful for determining whether replacement-cycle demand is industry-wide or Agilent-specific [#10-K-2025-12-22].

DHR

Broad diagnostics and analytical-instruments benchmark relevant to pathology and laboratory-workflow execution [#10-K-2025-12-22].

TMO

Large life-science tools and services benchmark for end-market demand and mix, although its broader portfolio makes it less comparable than a pure-play instrument vendor [#10-K-2025-12-22].

WAT

Direct analytical-instruments and laboratory-workflow comparator for evaluating replacement demand and service attachment; Agilent previously identified Waters as a principal competitor [#10-K-2025-12-22].